PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer - Loibl, Sibylle; Schneeweiss, Andreas; Sinn, Peter (Journal of clinical oncology, 2014)
Gesehen am16.02.2016